<PAGE>
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report January 31, 2000
DURAMED PHARMACEUTICALS, INC.
_________________________________________________________________
(Exact name of registrant as specified in its charter)
Delaware 0-15242 11-2590026
_________________________________________________________________
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
7155 East Kemper Road, Cincinnati, Ohio 45249 (513) 731-9900
_________________________________________________________________
(Address of principal executive offices)
INFORMATION TO BE INCLUDED IN THE REPORT
Items 1, 2, 3, 4, 6, 7, and 8 are not applicable and are omitted
from this Report.
Item 5. Other Events
____________
As previously reported, Duramed Pharmaceuticals, Inc.
in October 1999 settled certain litigation with Schein
Pharmaceutical, Inc. This Settlement called for the
payment of $7.5 million by Duramed to Schein in October
1999, and for the payment of a second $7.5 million to
Schein on January 20, 2000. The first $7.5 million was
paid on October 22, 1999. Duramed is now completing
financing for the second $7.5 million, and payment will
be made to Schein as soon as this financing is in place.
<PAGE>
SIGNATURES
__________
Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.
Date: January 31, 2000 DURAMED PHARMACEUTICALS, INC.
By: /s/ Timothy J. Holt
_____________________________
Timothy J. Holt
Senior Vice President-Finance
and Administration
